DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Although immune therapies, such as immune checkpoint inhibitors (ICIs), have significantly improved cancer outcomes, these therapies can also cause off-target tissue damage and response variability. The host microbiome affects ICI responsiveness and risk of immune-related adverse effects (irAEs), according to numerous lines of evidence. These developments show the possibility to control microbiome elements to improve the success of ICI because the microbiome is manipulable.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
